Nivolumab or atezolizumab in the second-line treatment of advanced non-small-cell lung cancer? Prognostic index based on real-world data

被引：0
|
作者：
Knetki-Wroblewska, M. [1 ]
Pluzanski, A. [1 ]
Tabor, S. [1 ]
Winiarczyk, K. [1 ]
Zaborowska-Szmit, M. [1 ]
Zajda, K. [1 ]
Zebrowska, A. Janowicz [1 ]
Piorek, A. [1 ]
Badurak, P. [1 ]
Jaskiewicz, P. [1 ]
Kowalski, D. M. [1 ]
Krzakowski, M. J. [1 ]
机构：
[1] Maria Sklodowska Curie Natl Res Inst Oncol, Lung Canc & Chest Tumors Dept, Warsaw, Poland
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1166
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1040P
引用
收藏
页码：S1030 / S1030
页数：1
相关论文
共 50 条
  • [31] Second-line treatment for advanced-stage non-small-cell lung cancer: Current and future options
    Ho, Cheryl
    Davies, Angela M.
    Lara, Primo N., Jr.
    Gandara, David R.
    CLINICAL LUNG CANCER, 2006, 7 : S118 - S125
  • [32] Treatment Monitoring Program for Implementation of Adherence to Second-Line Erlotinib for Advanced Non-Small-Cell Lung Cancer
    Gebbia, Vittorio
    Bellavia, Massimo
    Banna, Giuseppe Luigi
    Russo, Paolo
    Ferrau, Francesco
    Tralongo, Paolo
    Borsellino, Nicolo
    CLINICAL LUNG CANCER, 2013, 14 (04) : 390 - 398
  • [33] A prognostic model for platinum-doublet as second-line chemotherapy in advanced non-small-cell lung cancer patients
    Mo, Hongnan
    Hao, Xuezhi
    Liu, Yutao
    Wang, Lin
    Hu, Xingsheng
    Xu, Jianping
    Yang, Sheng
    Xing, Puyuan
    Shi, Youwu
    Jia, Bo
    Wang, Yan
    Li, Junling
    Wang, Hongyu
    Wang, Ziping
    Sun, Yan
    Shi, Yuankai
    CANCER MEDICINE, 2016, 5 (06): : 1116 - 1124
  • [34] First- and second-line treatment of advanced metastatic non-small-cell lung cancer: a global view
    Nicholas Thatcher
    BMC Proceedings, 2 (Suppl 2)
  • [35] Docetaxel as second-line chemotherapy for non-small-cell lung cancer
    Roila, F
    Del Favero, A
    Ballatori, E
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (21) : 3738 - 3738
  • [36] Second-line erlotinib for non-small-cell lung cancer Reply
    Ciuleanu, Tudor
    LANCET ONCOLOGY, 2012, 13 (04): : E142 - E142
  • [37] Second-line chemotherapy for non-small-cell lung cancer.
    Fossella F.V.
    Current Oncology Reports, 2000, 2 (1) : 96 - 101
  • [38] Second-line therapeutic options in non-small-cell lung cancer
    Vansteenkiste, Johan
    LUNG CANCER, 2006, 54 : S15 - S18
  • [39] Outcomes of patients in South Yorkshire with advanced non-small-cell lung cancer treated with second-line atezolizumab following induction with chemotherapy
    Ryan, A.
    Bates, E.
    Danson, S.
    Das, T.
    Fisher, P.
    Hatton, M.
    Lee, C.
    Young, R.
    Taylor, F.
    Marshall, R.
    LUNG CANCER, 2020, 139 : S55 - S55
  • [40] Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
    Gettinger, Scott
    Rizvi, Naiyer A.
    Chow, Laura Q.
    Borghaei, Hossein
    Brahmer, Julie
    Ready, Neal
    Gerber, David E.
    Shepherd, Frances A.
    Antonia, Scott
    Goldman, JonathanW.
    Juergens, Rosalyn A.
    Laurie, Scott A.
    Nathan, Faith E.
    Shen, Yun
    Harbison, Christopher T.
    Hellmann, Matthew D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (25) : 2980 - +
12345